LIXTE Biotechnology Holdings, Inc. announced the completion of the acquisition of Liora Technologies Europe Ltd.
The acquisition includes Liora's proprietary flagship technology LiGHT System for proton therapy.
Liora's LiGHT system offers advantages over current technologies and is installed at STFC's Daresbury Laboratory in the UK.
Entry into Radiotherapy Segment
LIXTE's acquisition of Liora marks its entry into the radiotherapy segment of cancer care.
Global Potential of LiGHT System
The LiGHT System is believed to have significant global potential and may set a new standard in cancer care.
Advancements in Cancer Treatment
The acquisition aims to advance modern cancer treatment with high-precision proton therapy.
Future Revenue Model
LIXTE plans to pursue a recurring revenue model through jointly operated treatment centers.
- The acquisition positions LIXTE to expand its capabilities in cancer treatment with cutting-edge technology.
- The LiGHT System's unique features are expected to enhance treatment effectiveness and scalability.
The acquisition of Liora Technologies' proton therapy platform marks a significant milestone in LIXTE's efforts to revolutionize cancer treatment.